Physician profile
Bethany Correlli
NPI 1497353973
$1,450.71
in general payments reported to CMS, 2019-2025
19 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.57 · 2024: $70.27 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.30 | 2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $320.40 | 2024-2025 | |
| Lilly USA, LLC | $192.58 | 2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $139.60 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.11 | 2024-2025 | Jardiance, Synjardy |
| Biohaven Pharmaceuticals, INC. | $61.05 | 2021 | |
| Dexcom, INC. | $53.45 | 2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $45.87 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $40.66 | 2025 | Voquezna |
| Exact Sciences Corporation | $32.83 | 2025 | The Cologuard Plus Collection Kit |
| Indivior INC. | $25.56 | 2025 | Sublocade |
| Astellas Pharma US INC | $25.48 | 2025 | Veozah |
| Almatica Pharma LLC | $23.97 | 2025 | Loreev Xr |
| Glaxosmithkline, LLC. | $18.55 | 2025 | Shingrix |
| Resmed Corp | $18.31 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.96 | 2025 | Xifaxan |
| Globus Medical, INC. | $17.86 | 2025 | Senza |
| Medtronic, INC. | $16.29 | 2025 | Closurefast |
| Takeda Pharmaceuticals U.S.A., INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Correlli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.